Using Metformin to Treat Ulcerative Colitis
Metformin, The Biguanide Derivative, as Adjuvant Therapy in Patients With Ulcerative Colitis Treated With Mesalamine
PHASE2 · Tanta University · NCT05574387
This study is testing if adding Metformin to the treatment plan can help adults with mild to moderate ulcerative colitis feel better.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 46 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Tanta University (other) |
| Locations | 1 site (Al Mansurah) |
| Trial ID | NCT05574387 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of Metformin as an additional therapy for patients suffering from ulcerative colitis, a chronic inflammatory bowel disease. The study aims to explore the potential benefits of Metformin in improving treatment outcomes for patients with mild to moderate forms of the condition. Participants will be adults aged 18 and older who have been diagnosed with ulcerative colitis and meet specific inclusion criteria. The trial will exclude individuals with severe disease or other significant health issues that could interfere with the study.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with mild to moderate ulcerative colitis.
Not a fit: Patients with severe ulcerative colitis or those with significant liver or kidney function abnormalities may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a new therapeutic option for patients with ulcerative colitis, potentially improving their quality of life.
How similar studies have performed: While the use of Metformin in inflammatory bowel diseases is an emerging area, there is limited prior research specifically targeting ulcerative colitis, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Age ≥ 18 years Both males and females will be included Negative pregnancy test and effective contraception Mild and moderate UC patients diagnosed and confirmed by the endoscope Exclusion Criteria: \- Breastfeeding Significant liver and kidney function abnormalities Diabetic patients Colorectal cancer patients Patients with severe UC Patients taking rectal or systemic steroids
Where this trial is running
Al Mansurah
- Faculty of Medicine, Mansoura University — Al Mansurah, Egypt (RECRUITING)
Study contacts
- Study coordinator: Mostafa Bahaa, PhD
- Email: mbahaa@horus.edu.eg
- Phone: 0201025538337
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Inflammatory Bowel Diseases